UltraGreen.ai gains Singapore approval for Verdye in regional push

The regulatory clearance anchors UltraGreen.ai's Southeast Asia expansion.

UltraGreen.ai has secured regulatory approval in Singapore for Verdye, or indocyanine green for injection, which will support its expasion in Southeast Asia.

In a press release, the company said the approval gives the company access to Singapore’s healthcare system, noting Singapore acts as a centre for clinical practice and regional influence in healthcare adoption.

The approval also supports its commercialisation efforts and partnerships with hospitals and healthcare institutions in the city-state.

Verdye is used in fluorescence-guided surgery with indocyanine green, applied in oncology, colorectal, reconstructive, and vascular procedures.

UltraGreen.ai develops a fluorescence-guided surgery platform combining pharmaceutical products, imaging hardware, and artificial intelligence-based data tools for surgical decision-making and procedural standardisation.

The company said the platform supports wider adoption of fluorescence-guided surgery across procedures.

Ravi Sajwan, CEO of UltraGreen.ai, said Singapore serves as a strategic market due to its healthcare system and regional role in clinical adoption across Southeast Asia, adding that the approval supports regulatory execution and the company’s regional strategy.

Verdye is approved in 41 countries, whilst the IC-Flow imaging system is approved in 45 markets.

UltraGreen.ai also referenced its recent initial public offering and regulatory approval of Verdye in the Philippines as part of its Southeast Asia expansion.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia